At the conclusion of this activity, learners should be able to:

  • Describe clinical trial data showing variation in how RAS mutant cancers respond to treatment
  • Describe ongoing studies subclassifying RAS mutants into those that are biomarkers for EGFR inhibitor sensitivity and for EGFR inhibitor resistance
  • Identify computational simulations as an emerging computational tool for studying pathogenic mutations and their response to treatment
Session date: 
10/29/2021 - 12:00pm to 1:00pm EDT

Please login or register to take this course.
Room Number: 
Zoom Meeting
Speaker Name: 
Edward Stites, MD, PhD, Salk Institute for Biological Studies